Hervé Hoppenot, Incyte CEO
Incyte pays out $70M to get hands on Medicxi-backed vitiligo biotech
The M&A wheels keep on turning in biotech — and this time it’s Incyte that gets to do the dealmaking.
The Delaware biotech put out word …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
